KyungDong Pharm home
Prescription Medicines

Esoprazol Tab. 40mg

Product Category
Peptic ulcer treatment
Active Ingredients
Esomeprazole Magnesium Trihydrate
Appearance
Pink round film-coated tablets
Reimbursement Code
648103720
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength
1 tablet
- Active ingredient: Esomeprazole magnesium trihydrate (micronized; in-house specification), 44.5 mg (equivalent to 40 mg of esomeprazole)
- Additives: Microcrystalline cellulose, magnesium hydroxide, sodium stearyl fumarate, acrylic pink (93A640002), Opadry II white (85F18422), low-substituted hydroxypropyl cellulose, crospovidone, triethyl citrate, povidone, D-mannitol, L-arginine

2. Effectiveness
1. Gastroesophageal reflux disease (GERD)
- Treatment of erosive reflux esophagitis
- Long-term maintenance therapy to prevent recurrence in patients with esophagitis
- Symptomatic treatment of gastroesophageal reflux disease without esophagitis
2. Antibiotic combination therapy to eradicate Helicobacter pylori
- Treatment of duodenal ulcer positive for Helicobacter pylori
- Prevention of recurrence in Helicobacter pylori positive peptic ulcer patients
3. Short-term therapy for the treatment of upper gastrointestinal symptoms (pain, discomfort, burning) related to the administration of non-steroidal anti-inflammatory drugs (COX-2 non-selective, selective)
4. Patients requiring continuous NSAID administration
- Treatment of gastric ulcers related to NSAID administration
- Prevention of gastric and duodenal ulcers related to NSAID administration
5. Treatment of Zollinger-Ellison syndrome
6. Maintenance therapy after induction of rebleeding due to gastric or duodenal ulcer by intravenous injection.

3. Dosage and dosage
This medicine should be swallowed with liquid such as water and should not be chewed or crushed.
1. Adult
1) Gastroesophageal reflux disease (GERD).
- Treatment of erosive reflux esophagitis: Administer 40 mg once a day for 4 weeks.
For patients whose esophagitis is not cured or whose symptoms persist, take the medication for 4 more weeks.
- Long-term maintenance therapy to prevent recurrence in patients with esophagitis: 20 mg once a day
- Symptomatic treatment of gastroesophageal reflux disease without esophagitis:
· Once a day, 20 mg once. If symptoms are not controlled after 4 weeks, additional treatment is required.
· Once symptoms are alleviated, subsequent symptoms are controlled by administering 20 mg once a day.
· In adults, 20 mg once a day can be administered whenever necessary. For patients at high risk of developing gastric or duodenal ulcers due to NSAID treatment, it is not recommended to administer the drug as often as needed to continuously control symptoms.
2) Antibiotic combination therapy to eradicate Helicobacter pylori
Administer 20 mg of this drug in combination with 1 g of amoxicillin and 500 mg of clarithromycin twice a day for 7 days.
3) Short-term therapy for the treatment of upper gastrointestinal symptoms (pain, discomfort, burning) related to the administration of non-steroidal anti-inflammatory drugs (COX-2 non-selective, selective)
- Once a day, 20 mg once. If symptoms are not controlled after 4 weeks, additional treatment is required. No clinical trials longer than 4 weeks were conducted.
4) Patients requiring continuous NSAID administration
- Treatment of gastric ulcers related to NSAID administration: 20 mg once a day. The treatment period is 4 to 8 weeks.
- Prevention of gastric ulcer and duodenal ulcer related to NSAID administration: 20 mg once a day.
5) Treatment of Zollinger-Ellison syndrome
The recommended initial dose is 40 mg twice daily. Thereafter, the dose should be adjusted for each patient, and treatment should be continued as long as clinical symptoms exist. According to clinical data, most patients can adjust the dose to 80 to 160 mg per day. Doses exceeding 80 mg per day should be taken in two divided doses.
6) Maintenance therapy after induction of rebleeding due to gastric or duodenal ulcer by intravenous injection.
Administer 40 mg once a day for 4 weeks after induction to prevent rebleeding due to gastric or duodenal ulcer by intravenous injection.
2. Youth over 12 years of age
1) Gastroesophageal reflux disease (GERD)
- Treatment of erosive reflux esophagitis: Administer 40 mg once a day for 4 weeks.
For patients whose esophagitis is not cured or whose symptoms persist, take the medication for 4 more weeks.
- Symptomatic treatment of gastroesophageal reflux disease without esophagitis:
· Once a day, 20 mg once. If symptoms are not controlled after 4 weeks, additional treatment is required.
· Once symptoms are alleviated, subsequent symptoms are controlled by administering 20 mg once a day.
· In adults, 20 mg once a day can be administered whenever necessary. For patients at high risk of developing gastric or duodenal ulcers due to NSAID treatment, it is not recommended to administer the drug as often as needed to continuously control symptoms.
3. Children under 12 years of age: There is no experience in administering this drug to children under 12 years of age.
4. Renal dysfunction: There is no need to adjust the dose. Since there are not many cases where it has been administered to patients with severe renal failure, it must be administered with caution.
5. Liver dysfunction: There is no need to adjust the dose in patients with mild to moderate liver dysfunction. For patients with severe hepatic impairment, the dose of this drug should not exceed 20 mg.
6. Elderly: There is no need to adjust the dose.

4. Precautions for use
1. Do not administer to the following patients.
1) Patients with a history of hypersensitivity to this drug, its components, or benzimidazoles
2) Patients with hypersensitivity to penicillin antibiotics (when combined with amoxicillin to eradicate Helicobacter pylori)
3) Patients with hypersensitivity to macrolide antibiotics (limited to combined use with clarithromycin to eradicate Helicobacter pylori)
4) Patients receiving terfenadine, cisapride, pimozide, and astemizole (limited to combined use with clarithromycin to eradicate Helicobacter pylori.) (See interaction section)
5) Patients receiving atazanavir and nelfinavir (see interaction section)
6) Nursing mothers
7) Patients with myocardial infarction and its history
8) Patients taking rilpivirine-containing preparations (see interaction section)

2. Adverse reactions
1) The following adverse reactions were confirmed or suspected in clinical trials and post-marketing surveillance. There was no dose correlation. Adverse reactions were classified according to frequency (often > 1/100, < 1/10; occasionally > 1/1,000, < 1/100; rarely > 1/10,000, < 1/1,000; very rare < 1/10,000).
- Blood and lymphatic system: rare leukopenia, thrombocytopenia, very rare agranulocytosis, pancytopenia
- Immune system: Rare hypersensitivity reactions such as fever, angioedema, anaphylactic reaction/shock, etc.
- Metabolism/Nutrition: Sometimes peripheral edema, rarely hyponatremia, very rarely hypomagnesemia (severe hypomagnesemia may cause hypocalcemia. Hypomagnesemia may also cause hypokalemia.)
- Mental system: sometimes insomnia, rarely agitation, mental confusion, depression, very rarely aggression, hallucinations
- Nervous system: frequent headache, occasional dizziness, paresthesia, drowsiness, rarely taste disturbance
- Vision: Rarely blurred vision
- Auditory and labyrinthine systems: sometimes dizziness (vertigo)
- Respiratory system: Rarely bronchospasm
- Gastrointestinal system: pancreatitis, frequent abdominal pain, constipation, diarrhea, abdominal distension, nausea and vomiting, sometimes dry mouth, rarely stomatitis, gastrointestinal candidiasis, very rarely microscopic colitis
- Hepatobiliary system: sometimes increased liver enzymes, rarely hepatitis with or without jaundice, very rarely liver failure, encephalopathy in patients with pre-existing liver disease.
- Skin and subcutaneous tissue: Occasionally dermatitis, itching, rash, urticaria, rarely hair loss, photosensitivity, very rarely erythema multiforme, mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), toxic epidermal necrolysis (Riel syndrome), acute generalized pustulosis erythroderma, drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome)
- Musculoskeletal system: fractures rarely, joint pain, muscle pain, very rarely muscle weakness
- Kidney and urinary system: very rarely interstitial nephritis
- Reproductive system: Very rarely, gynecomastia
- Whole body and administration site: Rarely, asthenia and increased sweating
- Infection: Clostridium difficile diarrhea (frequency unknown)
2) In addition, the following adverse reactions were reported to be or possibly related to this drug with an incidence of less than 1%.
- Whole body: abdominal distension, allergic reaction, back pain, chest pain, substernal chest pain, facial edema, facial flushing, fatigue, fever, influenza-like disorder, general edema, leg edema, malaise, pain, stiffness, asthenia, peripheral edema
- Cardiovascular system: flushing, hypertension, tachycardia
- Endocrine system: goiter
- Digestive system: Colon hypersensitivity, worsening constipation, indigestion, dysphagia, gastrointestinal dysplasia, epigastric pain, belching, esophageal disorder, frequent bowel movements, gastroenteritis, gastrointestinal bleeding, hiccups, melena, oral disorders, pharyngeal disorders, rectal disorders, gastrointestinal symptoms, increased blood gastrin, tongue disorders, tongue edema, ulcerative stomatitis, vomiting
- Hearing: earache, tinnitus
- Blood system: anemia, hypochromic anemia, cervical lymphadenopathy, nosebleeds, leukocytosis, leukopenia, thrombocytopenia
- Liver: bilirubinemia, abnormal liver function, increased ALT, increased AST
- Metabolism/Nutrition: Diabetes, hyperuricemia, hyponatremia, increased ALP, dry mouth, vitamin B12 deficiency, weight gain, weight loss
- Musculoskeletal system: worsening arthritis, arthropathy, cramps, fibromyalgia syndrome, hernia, polymyalgia rheumatica, arthralgia
- Mental nervous system: Anorexia, apathy, increased appetite, confusion, worsening depression, hypertonia, agitation, decreased sensation, erectile dysfunction, insomnia, migraine, worsening migraine, sleep disorder, tremor, dizziness, vertigo, visual field defect, paresthesia, drowsiness.
- Reproductive system: dysmenorrhea, menstrual disorders, vaginitis
- Respiratory system: worsening asthma, cough, difficulty breathing, laryngeal edema, pharyngitis, rhinitis, sinusitis
- Skin/Appendixes: Acne, anal itching, rash, erythematous rash, maculopapular rash, angioedema, dermatitis, itching, urticaria, increased sweating
- Special senses: otitis media, abnormal sense of smell, loss of taste, loss of sense of taste
- Urinary system: urinary abnormalities, albuminuria, cystitis, dysuria, fungal infection, hematuria, urinary frequency, candidiasis, genital candidiasis, polyuria
- Vision: Conjunctivitis, visual abnormality
- Adverse reactions discovered on endoscopy: duodenitis, esophagitis, esophageal stricture, esophageal ulcer, esophageal varices, gastric ulcer, gastritis, benign polyps or nodules, Barrett's esophagus, mucous membrane discoloration, hernia
3) The following are adverse reactions reported through post-marketing surveillance of proton pump inhibitors. Because these adverse reactions are voluntarily reported from an unspecified population, it is not always possible to reliably predict their incidence or establish a causal relationship with drug administration.
- Immune system: Systemic lupus erythematosus
- Skin and subcutaneous tissue system: Cutaneous lupus erythematosus
- Gastrointestinal system: gastric gland polyp
- Metabolism and nutritional system: hypocalcemia, hypokalemia
4) Rhabdomyolysis: Rhabdomyolysis may occur, so observe carefully. If symptoms including muscle pain, asthenia, increased creatinine kinase (creatine phosphatase), and increased blood and urine myoglobin appear, administration should be discontinued and appropriate measures should be taken.

3. General precautions
1) This drug may alleviate the symptoms of malignant tumor or delay the diagnosis, so if there are warning symptoms of suspected malignant tumor (unintentional significant weight loss, recurrent vomiting, difficulty swallowing, hematemesis, melena, etc.) and gastric ulcer is present or suspected, the drug must be administered after confirming that it is not malignant.
2) When treating with this drug for a long period of time (especially more than 1 year), patients should be examined regularly.
3) Patients taking this drug when necessary are advised to consult a doctor if there are any changes in symptoms. If this drug is prescribed for on-demand administration, interactions with other drugs due to fluctuations in blood concentration of this drug should be taken into consideration.
4) As a combination therapy with antibiotics to eradicate Helicobacter pylori, you should refer to the instructions for use of the antibacterial agent administered together with this drug. Because clarithromycin is a strong CYP3A4 inhibitor, contraindications and interactions of clarithromycin must be considered when administering eradication therapy to patients taking other drugs metabolized by CYP3A4, such as cisapride.
5) When stomach acidity decreases due to proton pump inhibitors, the number of bacteria normally present in the gastrointestinal tract increases. Treatment with this medicine may slightly increase the risk of infections of the gastrointestinal tract caused by bacteria such as Salmonella, Campylobacter, and Clostridium difficile. This is associated with an increased risk of Clostridium difficile diarrhea, and several observational studies have reported that this risk is particularly increased in hospitalized patients. This diagnosis should be considered when diarrhea symptoms do not improve. Clostridium difficile diarrhea has been reported during use of almost all antibacterial agents.
6) Some overseas epidemiological studies have reported that proton pump inhibitor treatment may be associated with an increased risk of hip, wrist, and spine fractures. The risk of fracture was increased in patients receiving higher doses than the recommended dose and in patients using the drug for long-term use of more than 1 year.
Although the causal relationship between omeprazole and esomeprazole and osteoporotic fractures has not been determined, appropriate clinical monitoring is recommended according to the latest clinical guidelines for patients at risk of developing osteoporosis and osteoporotic fractures.
7) Hypomagnesemia was rarely reported in patients treated with proton pump inhibitors for more than 3 months, and was most common in patients treated for more than 1 year. For most patients, magnesium supplementation and discontinuation of proton pump inhibitor administration are necessary to treat hypomagnesemia. Patients requiring long-term treatment or taking concomitant medications such as digoxin or drugs that cause hypomagnesemia (e.g. diuretics) require periodic monitoring of magnesium levels, including at the start of treatment. Serious adverse reactions include rigidity, arrhythmias, and seizures.
8) Interference with laboratory tests: Increased CgA (serum chromogranin A) levels may interfere with neuroendocrine tumor tests. To avoid this interference, esomeprazole administration should be temporarily discontinued at least 5 days before measuring CgA.
9) Methotrexate: There have been literature reports that when proton pump inhibitors and methotrexate are used together (mainly when using high doses, see precautions for the use of methotrexate), the serum concentration of methotrexate and/or its metabolites increases and persists, leading to methotrexate toxicity. When high doses of methotrexate are used, temporary discontinuation of the proton pump inhibitor may be considered (see Interaction section).
10) During treatment, the progress should be observed sufficiently and this drug should be administered at the minimum dose and appropriate treatment period depending on the symptoms.
11) Skin and systemic lupus erythematosus: Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking proton pump inhibitors. These cases occurred newly or due to worsening of existing autoimmune diseases. Most cases of lupus erythematosus caused by proton pump inhibitors were cutaneous lupus erythematosus.
The most common form of cutaneous lupus erythematosus reported in patients taking proton pump inhibitors is subacute cutaneous lupus erythematosus, which occurs within weeks to years of continuous drug treatment in patients ranging from infants to the elderly. In general, histological results showed no organ invasion.
Systemic lupus erythematosus has been reported less commonly than cutaneous lupus erythematosus in patients taking proton pump inhibitors. Proton pump inhibitor-related systemic lupus erythematosus usually shows milder symptoms than non-drug-induced systemic lupus erythematosus. Systemic lupus erythematosus mainly occurs within a few days to several years after initial drug treatment in young adults to the elderly. The majority of patients presented with a rash, but arthralgia and cytopenias were also reported.
Do not take proton pump inhibitors for longer than medically indicated. If a patient taking this drug develops symptoms or signs consistent with cutaneous lupus erythematosus or systemic lupus erythematosus, stop taking the drug and refer the patient to an appropriate specialist for evaluation. Most patients improved simply by discontinuing proton pump inhibitors within 4 to 12 weeks. Serological tests (e.g., antinuclear antibody (ANA)) may be positive, and high serological test results may take longer to resolve than clinical symptoms.
12) Fundic gland polyps: Use of proton pump inhibitors is associated with an increased risk of fundic gland polyps, especially when used for a long period of more than a year. Among patients using proton pump inhibitors, most patients who developed gastric fundic polyps were asymptomatic and discovered accidentally through endoscopy. Proton pump inhibitors should be used for the shortest period of time according to the symptoms being treated.
13) Severe skin adverse reactions: Severe skin adverse reactions (SCAR), including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with increased eosinophilia and systemic symptoms (DRESS syndrome), and acute generalized erythroderma pustulosis (AGEP), have been reported when using proton pump inhibitors. At the first sign of severe skin adverse reactions or hypersensitivity reactions, treatment with this drug should be discontinued and further evaluation considered.

4. Interaction
1) Due to the decrease in stomach acidity during administration of this drug, the absorption of drugs whose absorption mechanism is affected by stomach acidity may increase or decrease. As with other acid secretion suppressants or antacids, the absorption of ketoconazole, itraconazole, and erlotinib may be reduced and the absorption of digoxin may be increased during administration of this drug. In healthy volunteers, coadministration of omeprazole (20 mg per day) with digoxin increased the bioavailability of digoxin by 10% (up to 30% in 2 out of 10 volunteers). This drug is an isomer of omeprazole. Therefore, when this drug is administered in combination with digoxin, the patient's condition must be monitored.
2) This drug is metabolized by CYP2C19 and CYP3A4. Additionally, this drug inhibits CYP2C19, the main metabolic enzyme of this drug. When coadministered with drugs metabolized by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin, and warfarin, the plasma concentration of these drugs may increase, so a dose reduction of these drugs may be necessary. Co-administration of 30 mg of this drug with diazepam, a CYP2C19 substrate, decreased the clearance of diazepam by 45%. Co-administration of phenytoin and 40 mg of this drug in patients with epilepsy increased the trough plasma concentration of phenytoin by 13%. Monitor phenytoin plasma concentrations when starting or discontinuing treatment with this drug. Omeprazole (40 mg administered once daily) increased the Cmax and AUCτ of voriconazole (CYP2C19 substrate) by 15% and 41%, respectively.
In clinical trials, when 40 mg of this drug was co-administered to patients taking warfarin, the coagulation time was within the normal range. However, in post-marketing surveillance, several clinically significant increases in INR and prothrombin time were reported during co-administration of the two drugs, which can lead to abnormal bleeding and even death. Therefore, monitoring is necessary when starting or discontinuing co-administration of this drug with warfarin or other coumarin derivatives.
3) This drug is metabolized by CYP2C19 and CYP3A4. When this drug is administered simultaneously with clarithromycin (500 mg twice daily), a CYP3A4 inhibitor, the AUC of this drug is doubled. Co-administration of this drug with CYP2C19 or CYP3A4 inhibitors may more than double the exposure of this drug. Voriconazole, a CYP2C19 and CYP3A4 inhibitor, increased the AUCτ of omeprazole by 280%. For this reason, there is no need to adjust the dose of this drug. However, dose adjustment should be considered in patients with severe liver dysfunction and patients requiring long-term treatment.
4) Drugs known to induce CYP2C19, CYP3A4, or both (e.g., rifampicin and St. John's wort) may decrease esomeprazole serum concentrations by increasing esomeprazole metabolism. Avoid coadministration of this drug with rifampicin or St. John's wort.
5) In addition to this drug, omeprazole also acts as an inhibitor of CYP2C19. In a crossover study, when 40 mg of omeprazole was administered to healthy volunteers, the Cmax and AUC of cilostazol increased by 18% and 26%, respectively, and the Cmax and AUC of one of the active metabolites of cilostazol increased by 29% and 69%, respectively.
6) When omeprazole (40 mg administered once daily) and atazanavir 300 mg/ritonavir 100 mg were co-administered to healthy volunteers, atazanavir exposure was reduced (AUC, Cmax, and Cmin decreased by approximately 75%). Dosing of atazanavir 400 mg four times daily cannot offset the effect of omeprazole on atazanavir exposure. Proton pump inhibitors, including this drug, cannot be administered together with atazanavir.
7) Omeprazole has been reported to interact with several antiviral agents. Other than this reported interaction, the clinical significance and mechanism have not been determined.
Reduced gastric acidity during omeprazole administration may alter the absorption of antiviral agents.
Another possible mechanism of interaction is CYP2C19, and decreased serum levels of antiviral agents such as atazanavir and nelfinavir have been reported when coadministered with omeprazole, and coadministration is not recommended. In addition, increased serum levels have been reported with antiviral agents such as saquinavir. There are also antiviral agents whose serum levels do not change when administered in combination with omeprazole. Omeprazole and esomeprazole have similar pharmacodynamic/pharmacokinetic properties and should not be coadministered with antiviral drugs such as atazanavir and nelfinavir.
8) When cisapride and 40 mg of this drug were co-administered to healthy volunteers, the AUC of cisapride was increased by 32% and the elimination half-life was prolonged by 31%, but there was no significant increase in peak plasma concentration. This interaction did not alter the effects of cisapride on cardiac electrophysiology. In other words, in addition to the slight prolongation of the QTc interval caused by cisapride alone, the QTc interval was not further prolonged by co-administration of this drug and cisapride.
9) This drug did not have a clinically significant effect on the pharmacokinetics of amoxicillin or quinidine.
10) A short-term study evaluating the combined administration of this drug with naproxen or rofecoxib showed no clinically relevant pharmacokinetic interactions.
11) From the results of a study in healthy volunteers, clopidogrel (initial dose 300 mg/maintenance dose 75 mg per day) and esomeprazole (orally administered 40 mg per day) appeared to have a pharmacokinetic/pharmacodynamic interaction, which was shown to reduce platelet aggregation by an average of 14% and reduce exposure to the active metabolite of clopidogrel by an average of 40%. Based on these results, esomeprazole and clopidogrel should not be administered together.
12) In adverse reaction case reports, population pharmacokinetic studies, and retrospective studies, it has been reported that when methotrexate (mainly used in high doses, see precautions for the use of methotrexate) and proton pump inhibitors are used together, the serum concentration of methotrexate and/or its metabolite, hydroxymethotrexate, increases and is maintained, leading to methotrexate toxicity. However, formal drug interaction studies have not been conducted on high-dose methotrexate and proton pump inhibitors (see General Precautions).
13) If this drug is used together with tacrolimus, the serum level of tacrolimus may increase.
14) Antibiotic combination therapy for the eradication of Helicobacter pylori: When clarithromycin and/or erythromycin are administered together with pimozide, cardiac arrhythmias (including QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) occur, and this is because hepatic metabolism of these drugs is disturbed by clarithromycin and erythromycin, according to foreign post-marketing studies. and fatal cases have also been reported.
15) When this drug and rilpivirine are coadministered, the plasma concentration of rilpivirine may decrease (increased gastric pH), so coadministration should not be performed. This may reduce the therapeutic effect of rilpivirine.

5. Administration to pregnant women
There are limited data on exposure to this drug during pregnancy. Animal testing results showed no direct or indirect harmful effects related to embryo/fetal development. Animal testing of the racemic mixture showed no direct or indirect harmful effects on pregnancy, parturition, or postpartum development. However, caution should be exercised when prescribing this drug to pregnant women.

6. Administration to nursing mothers
It is not known whether this drug passes into human breast milk. Since studies have not been conducted on nursing mothers, this drug should not be administered during breastfeeding.

7. Treatment in case of overdose
Symptoms associated with planned overdose (limited experience with doses of 240 mg/day) are transient. There were no significant problems when 80 mg of this drug was administered once. No specific antidote is known. This drug is not dialyzed because it has a very high protein binding rate. Therefore, in case of overdose, symptomatic treatment and general maintenance treatment should be used.

8. Storage and handling precautions
1) Keep out of reach of children.
2) Be careful because changing it into another container may cause an accident or is undesirable in terms of maintaining quality.

9. Pharmaceutical equivalence test information
The test drug Esoprazole 40 mg (Esomeprazole Magnesium Trihydrate) [KyungDong Pharm Co., Ltd.] and the reference drug Nexium Tablet 40 mg (Esomeprazole Magnesium) [Korea AstraZeneca Co., Ltd.] were orally administered to healthy adults as a single tablet on an empty stomach in a 2 When comparative evaluation item values (AUCt, Cmax) were log-transformed and subjected to statistical processing, the 90% confidence interval of the mean difference was within log 0.8 to log 1.25, proving biological equivalence.
※ Refer to table attached document

5. How to save
Airtight container, stored at room temperature (1~30℃)

6. Packaging unit
14 tablets (7 tablets/Alu-Alu x 2)

7. Period of use
36 months from date of manufacture

Product Updates

Total 4items

No.Product NameDetailsDate of ChangeDownload
4Esoprazol Tab. 40mgPrecautions for use2024.03.27PDF0097_201507892_Precautions for use (Esoprazole tablet 40mg).pdf
3Esoprazol Tab. 40mgPrecautions for use2023.05.14PDF0013_201507892_Precautions for use (esoprazole tablet 40mg).pdf
2Esoprazol Tab. 40mgEsoprazole tablets 40 mg (precautions for use...2017.08.24HWP71_Esoprazole tablet 40 mg.hwp
1Esoprazol Tab. 40mgEsoprazole tablets 40 mg (precautions for use...2017.04.20HWP71_Esoprazole tablet 40 mg.hwp